Why we invested in Isomorphic Labs, Demis Hassabis' AI-native drug discovery company

aleximm · x · 2026-11-17

The investor behind Isomorphic Labs explains the thesis: AI-powered drug discovery is one of AI's largest opportunities. Founded and chaired by Sir Demis Hassabis — who won the 2024 Nobel Prize in Chemistry for protein structure prediction — Isomorphic aims to build an AI-native pharmaceutical company with a mission to solve all disease. President Max Jaderberg, a prominent ML researcher and operator, rounds out a team the investor calls the decisive factor.

Related event: Isomorphic Labs Raises $5 Billion to Pursue AI-Driven Drug Discovery(13 posts)→

Original post →

More from Venture

Venture channel →